The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Incyte Biosciences Distribution B.V.EU/1/13/839/006

Main Information

Trade NameIclusig
Active SubstancesPonatinib hci
Dosage FormFilm-coated tablet
Licence HolderIncyte Biosciences Distribution B.V.
Licence NumberEU/1/13/839/006

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE24 ponatinib


License statusAuthorised
Licence Issued21/11/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back